The only inclusion criterion was the need of a biological aortic valve replacement. There were no exclusion criteria.
The Trifecta valve was the only stented biological aortic valve used at Hospiten Rambla during the time period.
Echocardiography was performed at discharge in all patients.
All echocardiographic examinations were performed transthoracically by three experienced echocardiographers.
RESULTS
A total of 200 consecutive patients (115 males, 57.5%, and 85 females, 42.5%, with a mean age of 71.2 years ± 7.7 years, range 39 to 89 years) underwent aortic valve replacement with the Trifecta valve.
A total of 57% of patients received size 19 mm and 21 mm valves.
The surface area (BSA) was 1.86 ± 0.2 m 2 , range 1.5 to 2.6 m 2 .
Preoperative NYHA class was as follows:
At discharge, 92.5% of patients (n=185) were in NYHA classes I or II.
Peak and mean systolic pressure gradients are shown in Figure 1 .
Single-digit gradients across all valve sizes. Clinical Highlights The mean effective orifice areas (EOAs) ranged from 1.6 to 2.5 depending on the size of the prosthesis (Figure 2) . One patient (0.5%) had significant aortic insufficiency due to prosthetic endocarditis.
T R I F E C TA ™ T I S S U E V A LV E
Major complications during hospitalization included: atrial fibrillation: 18% (n=36); renal failure requiring hemofiltration: 3.5% (n=7); and stroke: 1.5% (n=3). Early mortality at 30 days was 2.5% (n=5), of which one case was valve-related. (Note: the valve-related death was due to unknown reasons.)
SUMMARY OF KEY FINDINGS
The Trifecta aortic valve exhibited promising early hemodynamic performance in a large prospective study of 200 consecutive patients:
-Mean gradients were in the single digits across all valve sizes.
-There were no instances of severe prosthesis-patient mismatch (PPM). Only 6 patients (3%) had mild-to-moderate PPM.
-Effective orifice areas were very good -1.6 cm 2 for the 19 mm valve to 2.5 cm 2 for the 27 mm valve.
The Trifecta valve was implanted easily with only a few technique modifications from the techniques used with other stented biological valves.
CONCLUSIONS
The Trifecta valve provides excellent early clinical and hemodynamic performance, providing a good alternative to other biological stented aortic valves.
Further evaluation is needed during follow-up. 
